• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

Misonix Commences International Distribution of Ultrasonic Wound Care System

Posted on: Monday, 1 October 2007, 09:00 CDT

Misonix, Inc. (Nasdaq: MSON), a developer of ultrasonic medical device technology for the treatment of cancer and other chronic health conditions, today announced that it has entered into an exclusive distribution agreement with SIAD Healthcare for sale of its SonicOne® Ultrasonic Wound Care System in Italy. Under the terms of the contract, SIAD has agreed to minimum purchase order provisions for the SonicOne for a term of three years, beginning September 30, 2007, and renewal thereafter upon mutual agreement by the companies.

In connection with the distribution agreement, SIAD will undertake promotional activities within Italy that include the development of collateral marketing material, participation in trade shows and presentation of clinical papers. The agreement announced today represents an expanded relationship between Misonix and SIAD, as the distributor has been marketing Misonix's neuroaspirator in Italy since 2004.

The SonicOne allows healthcare practitioners to remove necrotic tissue, biofilm, and other impediments to successful wound healing. Treatment with the SonicOne enables the creation of a wound bed of receptive tissue to accept current and future bio-active therapies, which is particularly important for the treatment of chronic wounds. The benefits of ultrasound as applied with the SonicOne are that it is naturally bacteriocidal, reduces the pain associated with standard sharp debridement performed manually with a scalpel, and stimulates the wound bed to develop key components of wound healing.

About Misonix:

Misonix, Inc. (NASDAQ: MSON) designs, develops, manufactures, and markets, therapeutic ultrasonic medical devices, and laboratory equipment. Misonix's therapeutic ultrasonic platform is the basis for several innovative medical technologies. Misonix has a minority equity position in Focus Surgery, Inc. which uses high intensity focused ultrasound technology to destroy deep-seated cancerous tissue without affecting surrounding healthy tissue. Addressing a combined market estimated to be in excess of $3 billion annually; Misonix's proprietary ultrasonic medical devices are used for wound debridement, cosmetic surgery, neurosurgery, laparoscopic surgery, and other surgical and medical applications. Additional information is available on the Company's Web site at www.misonix.com.

With the exception of historical information contained in this press release, content herein may contain "forward looking statements" that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Investors are cautioned that forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include general economic conditions, delays and risks associated with the performance of contracts, risks associated with international sales and currency fluctuations, uncertainties as a result of research and development, acceptable results from clinical studies, including publication of results and patient/procedure data with varying levels of statistical relevancy, risks involved in introducing and marketing new products, potential acquisitions, consumer and industry acceptance, litigation and/or court proceedings, including the timing and monetary requirements of such activities, the timing of finding strategic partners and implementing such relationships, regulatory risks including approval of pending and/or contemplated 510(k) filings, the ability to achieve and maintain profitability in the Company's business lines, and other factors discussed in the Company's Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company disclaims any obligation to update its forward-looking statements.

Source: Business Wire

More News in this Category